检索结果-南通市图书馆

E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma

引用

Chinese Medical Journal 2011年第7期124卷 1082-1087页

作者： WANG Hua Makoto Satoh CHEN Gui-ping LI De-chuan Hirofumi Hamada yoichi arai Department of Urology Zhejiang Cancer Hospital Hangzhou Zhejiang 310022 China Department of Urology Se-en Hospital Tagajyo Japan Department of Molecular Medicine Sapporo Medical University Sapporo Japan Division of Urology Chair of Surgery Tohoku University Graduate School of Medicine Sendai Japan

Background Our previous studies have demonstrated potent oncolysis efficacy of the E1A, E1B double-restricted replication-competent oncolytic adenovirus AxdAdB-3 for treatment of bladder cancer. Here, we reported the ... 详细信息

关键词： oncolysis adenovirus gemcitabine renal cell carcinoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Transition Behavior in the Use of Complementary and Alternative Medicine during Follow-up after Radical Prostatectomy: A Multicenter Survey in Japan

引用

Health 2010年第12期2卷 1460-1465页

作者： Koji Yoshimura Yoshiteru Sumiyoshi Toshiyuki Kamoto Osamu Ogawa yoichi arai Yoshiyuki Kakehi Akito Terai Hiroshi Kanamaru Mutsushi Kawakita Naoko Kinukawa 不详

We evaluated the prevalence of use of complementary and alternative medicine (CAM), as well as the transitional nature of its use, before and after radical prostatectomy in Japa-nese patients with localized prostate cancer. Methods: We enrolled 376 patients, who an-swered a self-administered questionnaire on CAM use, psychological health locus of control (HLC), and general-health-related quality of life (GHQL). Detailed information regarding CAM use according to the transtheoretical model, and the time at initiation and abandonment of CAM use were assessed. Medical information was also extracted from patient charts. Results: 45.7% of patients belonged to the “precontem-plation” stage, 29.8% to the “contemplation” stage, 1.9% to the “preparation” stage, 14.4% to the “action” stage, and 8.2% to the “relapse” stage. Although patient age and educational status had a significant impact on stage of CAM use, HLC and GHQL were not associated with them. The time-course of prevalence of CAM use during follow-up was divided into three phases: “initial,” “rapid-increase,” and “main-tenance”. Conclusions: Among patients under-going radical prostatectomy, non-users can be classified into several behavioral stages, while users do not use CAM constantly during fol-low-up.

关键词： Prostate Cancer Alternative Medicine Health Survey Health Locus Of Control Epidemiology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除肝细胞癌的治疗效果

引用

Gastroenterology Report 2021年第2期9卷 133-138,I0002页

作者： Atsushi Hiraoka Takashi Kumada Toshifumi Tada Chikara Ogawa Joji Tani Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Hidenori Toyoda Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Taeang arai Michitaka Imai Yohei Koizumi Shinichiro Nakamura Kojiro Michitaka yoichi Hiasa Masatoshi Kudo Gastroenterology Center Ehime Prefectural Central HospitalEhimeJapan Department of Gastroenterology and Hepatology Ogaki Municipal HospitalGifuJapan Department of Internal Medicine Himeji Red Cross HospitalHyogoJapan Department of Gastroenterology and Hepatology Takamatsu Red Cross HospitalTakamatsuJapan Department of Gastroenterology and Hepatology Kagawa universityKagawaJapan Department of Gastroenterology Osaka Medical CollegeOsakaJapan Division of Gastroenterology and Hepatology Department of Internal MedicineNippon Medical SchoolTokyoJapan Department of Gastroenterology and Metabology Ehime University Graduate School of MedicineEhimeJapan Center of Gastroenterology Teine Keijinkai HospitalSapporoJapan Department of Gastroenterology Saiseikai Niigata HospitalNiigataJapan Department of Hepatology Kagawa Prefectural Central HospitalTakamatsuJapan Department of Gastroenterology Okayama City HospitalOkayamaJapan Department of Gastroenterology Asahi General HospitalAsahiJapan Department of Gastroenterology Toyama University HospitalToyamaJapan Division of Gastroenterology and Hepatology Otakanomori HospitalKashiwaJapan Department of Gastroenterology Tokushima Prefectural Central HospitalTokushimaJapan Hepato-biliary Center Matsuyama Red Cross HospitalMatsuyamaJapan Department of Hepatology Hamamatsu University School of MedicineHamamatsuJapan Department of Gastroenterology Kindai UniversityOsakaJapan

背景:在日本,乐伐替尼可用于不可切除原发性肝癌的一线、二线或三线治疗。本研究评估新近研发的雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除的原发性肝癌的疗效。方法:2018年5月至2020年1月间在日本16家中心接受乐伐替尼治疗的385例... 详细信息

背景:在日本,乐伐替尼可用于不可切除原发性肝癌的一线、二线或三线治疗。本研究评估新近研发的雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除的原发性肝癌的疗效。方法:2018年5月至2020年1月间在日本16家中心接受乐伐替尼治疗的385例不可切除原发性肝癌患者中,我们将其中接受雷莫芦单抗作为下一线治疗的28例患者纳入研究,对其治疗效果进行回顾性分析。结果:28例患者中位年龄70岁,中位白蛋白-胆红素(ALBI)评分为2.19。28例患者中,23例为男性;21例为Child-Pugh A级,7例为Child-Pugh B级;3例为BCLC B期,25例为BCLC C期。雷莫芦单抗用于二线、三线和四线治疗的病例分别为14例、9例和5例患者。26例患者获得疗效评估,客观缓解率为3.8%(1/26),疾病控制率为42.3%(11/26);中位疾病进展时间为2个月。未继续接受雷莫芦单抗治疗的原因包括16例出现疾病进展和2例出现3级不良反应(消化道出血和腹水)。结论:我们的初步研究显示,对于乐伐替尼治疗进展的不可切除原发性肝癌,雷莫芦单抗并没有获得预期的治疗效果。

关键词： hepatocellular carcinoma ramucirumab lenvatinib sorafenib

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：